Can Endometrial Cytology Identify Patients Who Would Benefit from Immunotherapy?

Abstract

<b><i>Introduction:</i></b> Patients with polymerase epsilon (<i>POLE</i>) mutation (<i>POLE</i>mut) subtype, MMR-deficient (MMR-d) subtype as classified by The Cancer Genome Atlas (TCGA), and a high tumor mutation burden (TMB-high) potentially benefit from immunotherapy. However, characteristics of the cytological morphology within these populations remain unknown. <b><i>Methods:</i></b> DNA extracted from formalin-fixed paraffin-embedded tissues was subjected to next-generation sequencing analysis. Genomic mutations related to gynecological cancers, TMB, and microsatellite instability were analyzed and were placed in four TCGA classification types. The following morphological cytological investigations were conducted on endometrial cancer using a liquid-based preparation method, prior to the commencement of initial treatment: (i) cytological backgrounds; (ii) differences between each count of neutrophils and lymphocytes as described below. <b><i>Results:</i></b> Insignificant differences in the cytological background patterns of TCGA groups and TMB status were found. Although there was no significant difference in neutrophil count (<i>p</i> = 0.955) in the TCGA groups, <i>POLE</i>mut and MMR-d had significantly higher lymphocyte counts than no specific molecular profile (NSMP) (<i>p</i> = 0.019 and 0.037, respectively); furthermore, p53mut also tended to be significant (<i>p</i> = 0.064). Lymphocyte counts in TMB-high were also significantly greater than TMB-low (<i>p</i> = 0.002). <i>POLE</i>mut showed a positive correlation between TMB levels and lymphocyte counts. For predicting patients with <i>POLE</i>mut plus MMR-d, lymphocyte counts demonstrated a superior diagnostic accuracy of area under the curve (AUC) (0.70, 95% CI: 0.57–0.84), with a cutoff value of 26 high-power field. <b><i>Conclusion:</i></b> Lymphocyte count using liquid-based cytology for patients with endometrial cancer may predict <i>POLE</i>mut plus MMR-d of TCGA groups and TMB-high in those who can benefit from immunotherapy.